We report on 2 recombinant (r) live vaccine candidates that use different s
trategies to improve cell-mediated immunity for TB control: (i) the current
TB vaccine strain Mycobacterium bovis BCG, endowed with a pore-forming cyt
olysin; and (ii) rSalmonella typhimurium secreting a single immunodominant
antigen shared by BCG and M. tuberculosis.